News

You may sort news by title, date or business need. If you wish to detail your search, please select the categories from the left. If you wish to see events at which Quintiles is scheduled to participate, please select the events link from the top.

  • Sort by:
  • Most Recent
  • Title

  • QUINTILES ESTABLISHES EMERGING COMPANIES INSTITUTE

    November 7, 1995 - Quintiles Transnational Corp. (Nasdaq-NNM: QTRN) announced today the establishment of the Quintiles Emerging Companies Institute to offer small, specialized companies access to a full range of medical product development services and expert consultation. The Quintiles Emerging Companies Institute will provide customized product development services to the emerging companies market segment and will provide growth opportunities for Quintiles' contract research services.

  • QUINTILES TAKES OVER DRUG DEVELOPMENT FACILITY IN SCOTLAND

    March 6, 1995 - Quintiles Transnational Corp. (NASDAQ-NNM:QTRN) announced that a subsidiary, Quintiles Scotland Ltd., today completed agreements to acquire certain assets of a drug development facility located in Edinburgh, Scotland from Syntex Pharmaceuticals Limited, a member of the Roche group based in Basle, Switzerland. Quintiles previously had announced that it had entered into a letter of intent to acquire the facility.

  • QUINTILES CONSIDERS ACQUISITION IN SCOTLAND

    January 17, 1995 - Quintiles Transnational Corp. announced today that its subsidiary, Quintiles (UK ) Limited, has signed a non-binding letter of intent to acquire certain assets of a drug development facility from Syntex Pharmaceuticals Limited, a member of the Roche group in Basle, Switzerland. The facility is located in Edinburgh, Scotland. Pursuant to the proposed agreement, Quintiles would employ approximately 200 existing Syntex employees. The proposed transaction is subject to the negotiation and execution of a definitive agreement and other approvals.

Page 1 of 1 (3 results)